Kaleido Scope

Known Mutation Testing (KT2)

We offer targeted detection of a previously characterized mutation within the family. From a fresh EDTA blood sample, DNA is extracted directly and the target region is amplified and directly ...
The American Journal of Managed Care

HER2- Mutation Testing Considerations and Timing

Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...
ascopubs.org

Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing

The model suggests that negative KRAS findings are believable when the maximum of APC and TP53 frequencies is at least 8% (corresponding posterior probability of false negative <5%). Validation ...
Targeted Oncology

Navigating Complexity: Key Updates to ASCO's Living Guidelines for Stage IV Driver Mutation–Negative NSCLC

The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...
ascopubs.org

Podcast: Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer Rapid Recommendation Update

Dr. Angie DeMichele and Dr. Lynn Henry present the latest rapid recommendation impacting two ASCO guidelines. This update focuses on testing for ESR1 mutations in patients with hormone ...